We use essential cookies (authentication, your saved goals/stack) by default. With your permission we’ll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Clomiphene citrate (Clomid) — the racemic SERM (enclomiphene + zuclomiphene)
A racemic selective estrogen receptor modulator (SERM) that has been FDA-approved for decades for female ovulation induction, and is used off-label in men with secondary (low-LH) hypogonadism to raise endogenous testosterone. By blocking estrogen feedback at the hypothalamus it increases LH and FSH, driving the testes to make more testosterone — unlike testosterone gels/injections, which suppress both. Honest appraisal: clomiphene is the RACEMIC mixture of enclomiphene (trans, the active estrogen-antagonist isomer) and zuclomiphene (cis, a long-lived weakly estrogenic isomer that accumulates) — the zuclomiphene downside is the entire reason the single-isomer enclomiphene was developed. Male use is off-label, the evidence is mostly observational and surrogate-based (testosterone/LH/FSH), and there are NO long-term hard-outcome trials. It is NOT a longevity drug.
Prescription medication — not a dietary supplement
Clomiphene (Clomid) is a prescription (or investigational) drug, not a supplement. It is included here for reference because people research and discuss it (often used off-label) — not as a recommendation. Take it only under a qualified clinician's supervision and only as prescribed; do not source it from grey-market vendors, where identity, purity, and dosing are unverified. The evidence below reflects its clinical trials.
What the evidence says
Clomiphene (Clomid) doesn't have enough studies with structured effect-size data yet to pool a verdict. Browse the studies below for individual findings.
Most evidence is from high-quality meta-analyses and randomised trials published 1978–2026 with a typical study size of 86 participants.
Based on 356 studies · 54 meta-analyses · 280 RCTs · 1,911 total participants
Confidence
High confidenceBy outcome
Clomiphene is FDA-approved (since the 1960s) for female ovulation induction and is supported there by Cochrane-level synthesis — though the landmark NEJM PCOS trial showed letrozole beats it on live births. For male hypogonadism a systematic review/meta-analysis and long observational series consistently show it raises endogenous testosterone (via LH/FSH), but that use is OFF-LABEL, the evidence is dominated by observational/surrogate data, and there are NO long-term hard-outcome trials (cardiovascular, fracture, mood, mortality). As the racemic mixture it also carries the long-lived, weakly estrogenic zuclomiphene — the trade-off that motivated the single-isomer enclomiphene. Honest, evidence-backed but emerging.
293 randomised trials
76% were about Clomiphene (Clomid) in an audit of 50 of them
Every randomised or controlled trial of Clomiphene (Clomid) indexed in PubMed, not a hand-picked subset. Meta-analyses and systematic reviews are deliberately excluded from this count: most of them cover many compounds at once, so counting them would inflate it.
PubMed · as of Sep 2026
17 trials ongoing or recruiting · 162 completed on ClinicalTrials.gov
28 of the completed trials have posted results
Registered trials show research momentum for Clomiphene (Clomid), not proof of effect — a registration is a plan, and posted results are sponsor-reported, not peer-reviewed. They are never counted toward the evidence rating above.
Browse these trials on ClinicalTrials.govClinicalTrials.gov · as of Nov 2026
Clomiphene citrate (Clomid, Serophene) is a non-steroidal selective estrogen receptor modulator (SERM) that has been an FDA-approved first-line ovulation-induction agent in anovulatory women — including those with polycystic ovary syndrome (PCOS) — since 1967.
In men it is used OFF-LABEL to treat secondary (hypogonadotropic) hypogonadism, where the goal is to raise endogenous testosterone.
Chemically, clomiphene is a RACEMIC mixture of two stereoisomers: enclomiphene (the trans-isomer, a relatively pure estrogen-receptor antagonist that drives most of the testosterone-raising effect) and zuclomiphene (the cis-isomer, weakly estrogenic and very slow to clear).
On long-term clomiphene the serum zuclomiphene:enclomiphene ratio runs roughly 20:1 because zuclomiphene accumulates, and its urinary detection window can exceed four months after short-term use — the long-lived, partially estrogenic zuclomiphene is the reason the pure trans-isomer enclomiphene was developed as a cleaner alternative.
Mechanistically, clomiphene antagonizes estrogen receptors at the hypothalamus and pituitary; the brain reads this as low estrogen and releases the negative feedback that restrains gonadotropin-releasing hormone (GnRH).
More GnRH drives the pituitary to secrete more luteinizing hormone (LH) and follicle-stimulating hormone (FSH). In women, the resulting FSH/LH surge triggers follicular maturation and ovulation — the approved indication. Clomiphene can raise endogenous testosterone in selected men by increasing gonadotropin signalling.
Effects on sperm measures vary, and treatment does not guarantee preserved fertility, conception or live birth. Use requires an individual assessment and monitoring by the treating specialist. The evidence is two-sided.
For male hypogonadism, a 2022 systematic review and meta-analysis (Huijben, 19 studies, ~1,640 patients — but only four RCTs, the rest observational) found clomiphene reliably raised total testosterone (standardized increase ~2.6) along with free testosterone, LH, FSH and SHBG, improved Androgen Deficiency in Aging Males (ADAM) symptom scores, and reported side effects in under 10% of patients with no serious adverse events; long observational series (Katz/Moskovic) show testosterone roughly doubling and staying elevated for years, with improved bone density and symptom scores.
A separate meta-analysis in obesity-related functional androgen deficiency reached a similar conclusion. But the honest caveats are significant.
Male use is OFF-LABEL — clomiphene is FDA-approved only for female infertility — and the male evidence base is dominated by observational studies and surrogate endpoints (testosterone, LH/FSH), not hard outcomes; there are NO long-term randomized trials of cardiovascular events, fractures, mood, or mortality.
On the approved female side, even the head-to-head data are humbling: in the landmark NEJM PCOS trial (Legro 2014), LETROZOLE — an aromatase inhibitor — produced more live births (27.5% vs 19.1%) and higher ovulation rates than clomiphene, which is why letrozole has displaced clomiphene as first-line for PCOS in many guidelines.
Class side effects include visual disturbances (blurring, flashes, rarely hallucinations), mood changes, and hot flushes, and there is a plausible (uncharacterized) SERM-class thromboembolic concern.
And because clomiphene carries the long-lived zuclomiphene, animal work shows that unopposed high-dose zuclomiphene has pernicious effects on male reproductive tissues — the explicit rationale for monoisomeric enclomiphene. Clomiphene is used off label in men with selected causes of secondary hypogonadism.
The reviewed hormone and symptom outcomes do not establish that fertility is preserved; specialist assessment is needed. This is a hormonal/reproductive compound, not a longevity agent.
Clomiphene's trans-isomer (enclomiphene) antagonizes estrogen receptors at the hypothalamus and pituitary. The brain reads this as low estrogen and releases the negative feedback that normally restrains GnRH. The cis-isomer zuclomiphene is weakly estrogenic and long-lived.
Removing estrogen feedback increases pulsatile GnRH, driving the pituitary to secrete more luteinizing hormone (LH) and follicle-stimulating hormone (FSH) — the opposite of what exogenous testosterone does.
Clomiphene can raise endogenous testosterone in selected men by increasing gonadotropin signalling. Effects on sperm measures vary, and treatment does not guarantee preserved fertility, conception or live birth. Use requires an individual assessment and monitoring by the treating specialist. In women, the FSH/LH rise drives follicular maturation and ovulation, the approved indication.
Because clomiphene is racemic, repeated dosing accumulates the slow-clearing, weakly estrogenic zuclomiphene (serum ratio ~20:1 zuclomiphene:enclomiphene; urinary detection >4 months). This is the pharmacologic downside that motivated the pure trans-isomer enclomiphene.
How Clomiphene (Clomid) works — from molecular targets to health outcomes. Click an edge to see supporting research.This visualization is in beta — pathways are being refined and expanded.
Clomiphene is used off-label in selected men with secondary hypogonadism. Improvements in testosterone or semen measures do not guarantee fertility. Men who want current or future fertility should discuss options with a fertility specialist before starting testosterone.
This is the approved indication, but the landmark NEJM trial showed letrozole produced more live births in PCOS — discuss first-line choice with a fertility specialist.
Unlikely to help — clomiphene works by driving an intact pituitary-testis axis and cannot rescue failed testes.
No long-term cardiovascular or thrombosis outcome data exist for chronic male use; weigh the unknown long-term risk against the off-label status.
Exogenous androgens suppress the hypothalamic-pituitary axis that clomiphene works through; combining them is contradictory. Using testosterone can suppress sperm production. Discuss treatment and fertility goals with the prescriber.
Overlapping effects on the estrogen/HPG axis; stacking is common in TRT and fertility circles but is not well validated and can produce unpredictable estradiol and lipid effects.
Estrogen supplementation works against clomiphene's mechanism (it blocks estrogen-receptor feedback) and would blunt the testosterone/ovulation response.
Tip: A well-known clomiphene-class effect; stop and seek care if vision changes — usually reversible. Rare case reports of visual hallucinations exist.
Tip: Reported more with clomiphene than with letrozole in head-to-head trials; usually tolerable and transient.
Tip: Reported with clomiphene-class SERMs; monitor and discuss with the prescribing clinician.
Tip: Risk of multiple gestation and, rarely, ovarian hyperstimulation in ovulation induction; managed with monitoring and dose limits.
Tip: A plausible class concern for SERMs; long-term risk is not well characterized. Chest pain, sudden breathlessness, coughing up blood or collapse: call emergency services now. Sudden swelling of one leg or a warm, painful calf: get urgent medical assessment today.
Clomiphene (Clomid) has an evidence score of 4.8/10 — emerging evidence based on 359 indexed studies, including 2 meta-analyses. A racemic selective estrogen receptor modulator (SERM) that has been FDA-approved for decades for female ovulation induction, and is used off-label in men with secondary (low-LH) hypogonadism to raise endogenous testosterone. By blocking estrogen feedback at the hypothalamus it increases LH and FSH, driving the testes to make more testosterone — unlike testosterone gels/injections, which suppress both. Honest appraisal: clomiphene is the RACEMIC mixture of enclomiphene (trans, the active estrogen-antagonist isomer) and zuclomiphene (cis, a long-lived weakly estrogenic isomer that accumulates) — the zuclomiphene downside is the entire reason the single-isomer enclomiphene was developed. Male use is off-label, the evidence is mostly observational and surrogate-based (testosterone/LH/FSH), and there are NO long-term hard-outcome trials. It is NOT a longevity drug. Representative study: PMID 34933414.
Dosing for Clomiphene (Clomid): Off-label (male) / approved (female) — clinician-directed. For female ovulation induction the approved regimen is 50 mg once daily for 5 days starting early in the cycle, titrated up to 100 mg if needed (the US label does not recommend more than 100 mg a day for 5 days). For off-label male hypogonadism, observational studies used roughly 25-50 mg daily or every other day (25 mg/day is the most common starting dose), titrated to testosterone and LH/FSH response. There is no FDA-approved male dose. Individual needs vary, so check the right dose for you with a healthcare provider.
Timing is flexible for Clomiphene (Clomid) — consistent daily use matters more than the time of day. Taken as an oral tablet.
Clomiphene (Clomid) should be used with caution — talk to a healthcare provider before taking it. Reported side effects include venous thromboembolism, visual disturbances (blurring, flashes, floaters; rarely hallucinations), ovarian hyperstimulation / multiple pregnancy (female use). How often they occur is not established for all of them. Use caution if any of these apply to you: Pregnancy (clomiphene is contraindicated once pregnancy is established); Liver disease, undiagnosed abnormal uterine bleeding, or ovarian cysts not due to PCOS (per the approved female label); Primary (testicular) hypogonadism in men — needs an intact pituitary/testis axis to work.
What side effects does Clomiphene (Clomid) have?Don't take this if…
Enclomiphene
Too few graded studiesThe trans-isomer of clomiphene — a selective estrogen receptor modulator (SERM) used investigationally as a testosterone therapy. By blocking estrogen feedback at the hypothalamus it raises LH, FSH, and endogenous testosterone. Honest appraisal: Phase-2/3 RCTs show it raises testosterone — but it is NOT FDA-approved (Androxal failed to gain approval) and is compounded, and there are NO long-term hard-outcome trials (cardiovascular, bone, mortality).
Testosterone (TRT)
Too few graded studiesThe primary male androgen and a prescription medicine with US FDA-approved products for specified causes of male hypogonadism, and a Schedule III controlled substance in the US. For men with genuinely low testosterone, randomized trials show real benefits: the Testosterone Trials (TTrials) improved sexual function, mood, anemia and bone density in older hypogonadal men, and the large TRAVERSE trial found TRT non-inferior to placebo for major cardiac events. But those benefits were modest and indication-specific, NOT a longevity or anti-aging result. It is prescription-only in Germany and Austria. Non-medical, supraphysiologic and 'anti-aging' use is not established as safe or effective for longevity and carries serious harms — erythrocytosis, suppressed sperm production/fertility, cardiovascular and psychiatric risk. This is a harm-reduction reference, not a recommendation, and testosterone is NOT a dietary supplement.
CoQ10
Likely helpsA lipid-soluble antioxidant central to mitochondrial energy production, with the strongest trial support for fertility/IVF outcomes and heart failure.
DHEA
Probably helpsAdrenal hormone precursor that declines with age. In postmenopausal women with normal adrenal function, trials found no effect on sexual symptoms or metabolic markers.
Explore: Best supplements for Women's HealthBest supplements for Men's Health
Reviewed by Dr. Baher Al Hakim · Last reviewed June 2026 · evidence from 382 studies · how we score · editorial policy
This information is for educational purposes only. It is not a substitute for professional medical advice. Always consult a qualified healthcare provider before starting, stopping, or changing any supplement or medication.
Tap node to isolate • Pinch to zoom • Tap edge for research